News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
BioLineRx Ltd. Announces New Results Confirming the Mode of Action of Its Anti-Psychotic Drug- BL-1020
June 22, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
JERUSALEM--(BUSINESS WIRE)--BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, announced today new results confirming its GABA enhanced BL-1020 drug’s MOA.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Asia
MORE ON THIS TOPIC
autoimmune disease
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study
September 23, 2026
·
2 min read
·
Tristan Manalac
Kidney disease
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
September 23, 2026
·
2 min read
·
Annalee Armstrong
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
·
2 min read
·
Tristan Manalac
ALS
Ionis-Otsuka offer ‘groundbreaking’ improvement in function and survival for genetic type of ALS
September 23, 2026
·
4 min read
·
Heather McKenzie
